煌上煌(002695.SZ):三董事及高管減持期過半 累計減持1萬股
格隆匯10月18日丨煌上煌(002695.SZ)公佈,公司於2019年6月26日披露了《關於部分董事、高級管理人員擬減持股份的預披露公告》,公司董事及高管範旭明、章啟武、曾細華擬自2019年7月17日至2020年1月16日期間,以集中競價或大宗交易方式合計減持數量不超過97.5290萬股公司股票,佔公司總股本的0.19%。
截至2019年10月18日,範旭明、曾細華、章啟武此次減持計劃實施時間已過半。範旭明於2019年9月20日以14.50元/股一次性減持了1萬股公司股票,此次減持的股份來源為公司股權激勵計劃授予的限制性股票已解鎖的部分股份;曾細華、章啟武均未減持公司股份。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.